In addition, a Phase 2 randomized trial of perioperative propranolol, a β-blocker, and etolodac in breast cancer patients reported normalization of IL-6 and CRP, decreased EMT, and decreased tumor-infiltrating monocytes [131]. The gene discussed is IL6; the disease is breast carcinoma.